Aurobindo’s Parkinson’s drug cleared

Aurobindo Pharma has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Entacapone tablets. The approved product is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Comtan tablets of Orion Corporation. Entacapone tablets are used in the treatment of Parkinson's disease and has an estimated market size of $59 million for the 12 months ending April 2015, according to IMS. Aurobindo has also received the US regulator’s nod to manufacture and market Azithromycin for injection.